Development and optimisation of downstream processing for next generation biotherapeutics

近年来，“下一代”基于蛋白质的治疗药物得到了快速发展，但仍然需要新的制造工艺，以医疗保健提供者能够负担得起的价格提供这些药物。这些新疗法首次可以安全地修改患者的DNA，或利用人体自身的免疫系统来治疗遗传性疾病，神经系统疾病和癌症。然而，为了实现这种临床功能，治疗性蛋白质的复杂性和大小已经增加。这意味着现有的净化技术已经无法有效地应用于这种新的应用中。该项目旨在建立在现有的合作和可行性数据的基础上，开发新的纯化工具和策略，可应用于一系列下一代生物治疗药物，以使其具有成本效益的制造，以医疗保健支付者可接受的价格为患者提供新型疗法。

In recent years there has been rapid development of a "Next Generation" of protein-based therapeutics, yet the need remains for new manufacturing processes that can deliver these at a price healthcare providers can afford. For the first time these new therapies can safely modify a patient's DNA, or harness the body's own immune system, to treat inherited diseases, neurological conditions, and cancer. However, to achieve this clinical functionality the complexity and size of the therapeutic protein has increased. This has meant that existing purification technologies have been unable to be applied effectively in this new application. This project aims to build on existing collaborations and feasibility data to develop new purification tools and strategies that can be applied across a range of next generation biotherapeutics to enable their cost effective manufacture delivering novel therapies to patients at an aceeptable price for healthcare payers.